Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen

Infection and Immunity

Volumn 81, Issue 1, 2013, Pages 278-284

  Verma, Anita ^a   McNichol, Beth ^a,d   Domínguez Castillo, Rocío I ^a   Amador Molina, Juan C ^a   Arciniega, Juan ^a   Reiter, Karine ^b   Meade, Bruce ^c   Ngundi, Miriam ^a   Stibitz, Scott ^a   Burns, Drusilla L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Meade Biologics   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALUMINUM; ANTHRAX VACCINE; ASPARAGINE; ASPARTIC ACID; BACTERIAL ANTIGEN; GLUTAMINE; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL ACTIVITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DEAMINATION; DRUG FORMULATION; DRUG STORAGE; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHELF LIFE; SITE DIRECTED MUTAGENESIS; WILD TYPE;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; ASPARAGINE; BACILLUS ANTHRACIS; CELLS, CULTURED; FEMALE; MACROPHAGES; MICE; MUTAGENESIS, SITE-DIRECTED; VACCINES, SYNTHETIC;

EID: 84871865748     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00863-12     Document Type: Article

References (29)

1. Collier RJ, Young JA. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45-70.
2. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
3. Little SF, Ivins BE, Fellows PF, Friedlander AM. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175.
4. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
5. Baillie LW. 2009. Is new always better than old? The development of human vaccines for anthrax. Hum. Vaccin. 5:806-816.
6. Aswad D (ed). 1995. Deamidation and isoaspartate formation in peptides and proteins. CRC Press, Boca Raton, FL.
7. Reissner KJ, Aswad DW. 2003. Deamidation and isoaspartate formation in proteins: unwanted alterations or surreptitious signals? Cell. Mol. Life Sci. 60:1281-1295.
8. Robinson NE, Robinson ZW, Robinson BR, Robinson AL, Robinson JA, Robinson ML, Robinson AB. 2004. Structure-dependent nonenzymatic deamidation of glutaminyl and asparaginyl pentapeptides. J. Pept. Res. 63:426-436.
9. Hains PG, Truscott RJ. 2010. Age-dependent deamidation of lifelong proteins in the human lens. Invest. Ophthalmol. Vis. Sci. 51:3107-3114.
10. Lapko VN, Purkiss AG, Smith DL, Smith JB. 2002. Deamidation in human gamma S-crystallin from cataractous lenses is influenced by surface exposure. Biochemistry 41:8638-8648.
11. Watanabe A, Takio K, Ihara Y. 1999. Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. J. Biol. Chem. 274:7368-7378.
12. Robinson NE, Robinson AB. 2004. Amide molecular clocks in Drosophila proteins: potential regulators of aging and other processes. Mech. Ageing Dev. 125:259-267.
13. Robinson AB, Robinson LR. 1991. Distribution of glutamine and asparagine residues and their near neighbors in peptides and proteins. Proc. Natl. Acad. Sci. U. S. A. 88:8880-8884.
14. Robinson NE, Robinson AB. 2001. Molecular clocks. Proc. Natl. Acad. Sci. U. S. A. 98:944-949.
15. Moss CX, Matthews SP, Lamont DJ, Watts C. 2005. Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules. J. Biol. Chem. 280:18498-18503.
16. McAdam SN, Fleckenstein B, Rasmussen IB, Schmid DG, Sandlie I, Bogen B, Viner NJ, Sollid LM. 2001. T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation. J. Exp. Med. 193:1239 -1246.
17. Zomber G, Reuveny S, Garti N, Shafferman A, Elhanany E. 2005. Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen. J. Biol. Chem. 280:39897-39906.
18. Powell BS, Enama JT, Ribot WJ, Webster W, Little S, Hoover T, Adamovicz JJ, Andrews GP. 2007. Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity. Proteins 68:458-479.
19. Ribot WJ, Powell BS, Ivins BE, Little SF, Johnson WM, Hoover TA, Norris SL, Adamovicz JJ, Friedlander AM, Andrews GP. 2006. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine 24:3469-3476.
20. Janes BK, Stibitz S. 2006. Routine markerless gene replacement in Bacillus anthracis. Infect. Immun. 74:1949-1953.
21. Bannam TL, Rood JI. 1993. Clostridium perfringens-Escherichia coli shuttle vectors that carry single antibiotic resistance determinants. Plasmid 3:233-235.
22. Thouvenot B, Charpentier B, Branlant C. 2004. The strong efficiency of the Escherichia coli gapA P1 promoter depends on a complex combination of functional determinants. Biochem. J. 383:371-382.
23. Rosovitz MJ, Schuck P, Varughese M, Chopra AP, Mehra V, Singh Y, McGinnis LM, Leppla SH. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and toa neutralizing monoclonal antibody. J. Biol. Chem. 278:30936-30944.
24. Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, Steward-Clark E, Stamey KL, Schmidt DS, Stinson KW, Freeman AE, Elie CM, Martin SK, Greene C, Aubert RD, Glidewell J, Perkins BA, Ahmed R, Stephens DS. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis. 190:1228-1236.
25. Verma A, Wagner L, Stibitz S, Nguyen N, Guerengomba F, Burns DL. 2008. Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay. Clin. Vaccine Immunol. 15:1737-1741.
26. Ngundi MM, Meade BD, Lin TL, Tang WJ, Burns DL. 2010. Comparison of three anthrax toxin neutralization assays. Clin. Vaccine Immunol. 17:895-903.
27. Whitmore L, Wallace BA. 2004. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 32:W668-W673.
28. Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL. 2012. Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant. Clin. Vaccine Immunol. 19:1465-1473.
29. Kosky AA, Dharmavaram V, Ratnaswamy G, Manning MC. 2009. Multivariate analysis of the sequence dependence of asparagine deamidation rates in peptides. Pharm. Res. 26:2417-2428.